^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).
Published date:
05/19/2021
Excerpt:
Patients harboring a KRAS mutation had 3.4 times the odds of responding to treatment with binimetinib as patients without KRAS mutation...longer PFS were seen in those patients with LGSOC treated with binimetinib who harbored MAPK mutations, most commonly in KRAS.
DOI:
10.1200/JCO.2021.39.15_suppl.5519
Trial ID:
